[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371775-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371775-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","patterns-of-her2-expression-in-metastatic-prostate-and-urothelial-cancers-implications-for-her2-targeted-therapies","Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers - Implications for HER2-Targeted Therapies","","HER2 is an oncogenic driver and a predictive biomarker for HER2-targeted therapies. Despite approvals of HER2-directed agents such as fam-trastuzumab deruxtecan, the distribution of HER2 expression in advanced prostate cancer and urothelial carcinoma remains insufficiently defined. Using a validated IHC assay on tissue microarrays, HER2 protein expression was scored with standardized gastric criteria and ERBB2 alterations were profiled in a subset. HER2 was low and heterogeneous in metastatic prostate cancer, whereas urothelial carcinoma showed more frequent and consistent high expression, supporting careful HER2 assessment and patient selection.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/patterns-of-her2-expression-in-metastatic-prostate-and-urothelial-cancers-implications-for-her2-targeted-therapies/371775/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/patterns-of-her2-expression-in-metastatic-prostate-and-urothelial-cancers-implications-for-her2-targeted-therapies/371775.png","ImageObject",300,407,{"name":42,"@type":43},"Grenda","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-20","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How was HER2 expression evaluated in metastatic prostate cancer and urothelial carcinoma?","Question",{"text":63,"@type":64},"HER2 protein expression was assessed using a validated IHC assay on tissue microarrays, with scoring performed using standardized gastric cancer criteria.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What were the key differences in HER2 expression patterns between prostate cancer and urothelial carcinoma?",{"text":68,"@type":64},"Metastatic prostate cancer showed low, heterogeneous HER2 expression with no 3+ cases and only a small fraction with 2+ expression. Urothelial carcinoma demonstrated more frequent and more uniform expression across metastases, including 2+ and 3+ cases.",{"name":70,"@type":61,"acceptedAnswer":71},"How do ERBB2 copy-number gains relate to HER2 protein expression in prostate cancer?",{"text":72,"@type":64},"Low-level ERBB2 copy-number gains were observed in some tumors but did not correlate with HER2 protein expression in the reported analysis.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371775,1790363031,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":124,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7971474921005,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-25-0069](https://doi.org/10.1158/2767-9764.CRC-25-0069)  OPEN ACCESS  \nPatterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies  \nHyun Jung Lee1,2,3, Roman Gulati4, Erolcan Sayar5, Radhika A. Patel5, Pushpa Itagi5, Helen M. Richards5, Thomas Persse5, Sonali Arora5, Ilsa Coleman5, Mohamed Adil5, Samantha L. Schuster5, Farinaz Shokri5, Jonathan L. Wright6, Evan Y. Yu4,7, Lawrence D. True1, Meagan Chambers8, Jessica E. Hawley4,7,  \nHeather H. Cheng4,7, Michael T. Schweizer4,7, Petros Grivas4,7, Peter S. Nelson5,7, R. Bruce Montgomery4,7, Andrew C. Hsieh5,7, Funda Vakar-Lopez1,5, Colm Morrissey6, Hung-Ming Lam6, Gavin Ha5, Maria S. Tretiakova1, Michael C. Haffner1,4,5, and Ruben Raychaudhuri4,7  \n􀀶  \nABSTRACT  \nHER2 is an oncogenic driver in multiple cancers and a predictive biomarker for HER2-targeted therapies. Although HER2-directed therapies like fam-trastuzumab deruxtecan are approved for HER2-positive breast and other solid tumors, the landscape of HER2 expression in advanced prostate cancer and urothelial carcinoma remains inadequately characterized. We evaluated HER2 protein expression in metastatic prostate cancer and urothelial carcinoma using a validated IHC assay on tissue microarrays constructed from the University of Washington Tissue Acquisition Necropsy Program. HER2 expression was scored using standardized gastric cancer criteria. Genomic analysis of ERBB2 alterations was conducted on a subset of samples. HER2 expression heterogeneity and its relationship with other surface markers were also evaluated. In the prostate cancer cohort (n ¼ 52 patients, 1–19 tumors per patient), HER2 expression was low, with no 3+ expression observed and only five (10%) patients exhibiting 2+ expression. Low-level ERBB2 copy-number gains were observed in some tumors but did not correlate with HER2 protein expression (P ¼ 0.2) . In urothelial carcinoma  \n(n ¼ 20, 2–6 tumors per patient), HER2 expression was more frequent, with ≥2+ expression observed in six (30%) cases and 3+ expression observed in three (15%) cases in at least one tumor. Urothelial carcinoma samples showed less heterogeneity, with more consistent expression across metastases. HER2 overexpression is rare and heterogeneous in metastatic prostate cancer, limiting its utility as a therapeutic target. HER2 expression is more prevalent and uniform in urothelial carcinoma. These findings underscore the importance of comprehensive HER2 assessment in advanced urothelial carcinoma and suggest that success of HER2-directed therapies in prostate cancer will require careful case selection.  \nSignificance: This study demonstrates that HER2 is rarely overexpressed in metastatic prostate cancer but is more common and consistent inurothelial carcinoma. These findings highlight the need for HER2 testing in urothelial cancer and suggest that HER2-targeted therapies in prostate cancer will require careful patient selection.  \n1Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington. 2Department of Pathology, Pusan National University School of Medicine, Yangsan, Korea. 3Pusan National University Yangsan Hospital, Yangsan, Korea. 4Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington. 5Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington. 6Department of Urology, University of Washington, Seattle, Washington. 7Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington. 8Department of Pathology, Stanford University, Stanford, California.  \nCorresponding Authors: Michael C. Haffner, Fred Hutchinson Cancer Center, 1100 Fairview Avenue, Seattle, WA 98109. E-mail: [mhaffner@fredhutch.org](mhaffner@fredhutch.org); and Ruben Raychaudhuri, [rraych@uw.edu](rraych@uw.edu)  \n[doi:](doi: 10.1158/2767-9764)[ 10.1158/2767-9764](doi: 10.1158/2767-9764) .CR","cbCait0DPc6yle9K","https://ap.wps.com/l/cbCait0DPc6yle9K","pdf",8241784,"English","# Abstract\n# Introduction\n## HER2 biology and clinical relevance\n## HER2-targeted therapies and rationale\n## Need to define HER2 landscape in advanced prostate and urothelial cancers","[{\"question\":\"How was HER2 expression evaluated in metastatic prostate cancer and urothelial carcinoma?\",\"answer\":\"HER2 protein expression was assessed using a validated IHC assay on tissue microarrays, with scoring performed using standardized gastric cancer criteria.\"},{\"question\":\"What were the key differences in HER2 expression patterns between prostate cancer and urothelial carcinoma?\",\"answer\":\"Metastatic prostate cancer showed low, heterogeneous HER2 expression with no 3+ cases and only a small fraction with 2+ expression. Urothelial carcinoma demonstrated more frequent and more uniform expression across metastases, including 2+ and 3+ cases.\"},{\"question\":\"How do ERBB2 copy-number gains relate to HER2 protein expression in prostate cancer?\",\"answer\":\"Low-level ERBB2 copy-number gains were observed in some tumors but did not correlate with HER2 protein expression in the reported analysis.\"}]","Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers - Implications for HER2-Targeted Therapies | PDF",1790192837,25,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5bb2882e45d67cf5c43592d6e0ee45d3.webp",983,1263,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e29c1ab9f82ed754d4068ea965ab5478.webp",982,1262,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/973d3cda2d57962aaa454f0bbfc8b257.webp",981,1261,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/50f9f5e390a3a702c6f7d8db28a95383.webp",980,1259]